Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + albumin-bound paclitaxel + apatinib in advanced triple-negative breast cancer
CTR20200605Phase 3Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Hengrui Therapeutics. Primary endpoints: Progression-free survival (PFS) in PD-L1 positive population and Progression-free survival (PFS) in ITT population. Started Apr 2020; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20200605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200605.